Biotech

CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share, before underwriting discounts. As quoted in the press release: In addition, underwriters have a 30-day option to purchase …

CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share, before underwriting discounts.

As quoted in the press release:

In addition, underwriters have a 30-day option to purchase up to an additional 631,578 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $200 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about September 25, 2018, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-managers for the offering.

Click here to read the full press release.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×